Cinfina Pharma

Year Invested/Status: 2021/Active
Motivation: Obesity is an alarming global public health priority with well-established links to serious diseases including type 2 diabetes, coronary heart disease, stroke, cancer, and chronic obstructive pulmonary disease. While the use of GLP-1s to treat obesity has had dramatic uptake, there is still a tremendous need for more effective therapies with greater weight loss potential.

Lead Program(s): CinFina is developing a series of mono and combination biologic therapies, CIN-109, CIN-110, CIN-209 and CIN-210, currently ranging from pre-clinical to Phase 1. The CinFina portfolio includes long-acting GLP-1’s that have the potential to transform the treatment of obesity and related cardio-metabolic diseases. 

Pre-Clinical

Phase 1

Phase 2

Phase 3

CIN-109
Metabolic Diseases
CIN-110
Metabolic Diseases
CIN-209
Metabolic Diseases
CIN-210
Metabolic Diseases

INVESTOR INQUIRIES

CAREER INQUIRIES

GENERAL INQUIRIES